Human Tsp 1, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human tsp 1/product/ATCC
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
1) Product Images from "Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy"
Article Title: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Journal: Proceedings of the National Academy of Sciences of the United States of America
Figure Legend Snippet: ( A ) Northern blot analysis with its densitometric quantification ( Upper Right ) and Western blot analysis ( Lower Right ) of human dermal microvascular endothelial cell samples after 6 days of low-dose treatment with different cytotoxic drugs. β-Actin and CRM-1 were used as loading controls. ( B ) Human TSP-1 competitive enzyme immunoassay of vascular endothelial cell-conditioned media after 6 days of treatment using low concentrations of different cytotoxic drugs. The results are expressed as the percentage increase of secreted TSP-1 versus control samples and are the mean of two independent experiments with at least two replicates per sample. ( C ) Effect of protracted (144 h) low-dose cytotoxic drug treatments, in the presence or absence of neutralizing monoclonal antibody A4.1 directed against human TSP-1, on in vitro microvascular endothelial cell proliferation. Shown are mean values ± SEM.
Techniques Used: Northern Blot, Western Blot, Enzyme-linked Immunosorbent Assay, In Vitro
Figure Legend Snippet: Effects of MTD CTX (150 mg/kg i.v.), which was then switched to low-dose CTX (25 mg/kg p.o.) or normal saline on LL/2 tumor in syngeneic C57BL/6 mice. The two regimens were compared in wild-type ( A ) and TSP-1-null ( B ) mice. Results showed a complete loss of antitumor activity after a continuous low-dose CTX in TSP-1-null C57BL/6 mice ( B ) compared with wild-type controls ( A ), whereas the MTD regimen suppressed tumor growth to an equivalent extent in both types of mice.
Techniques Used: Mouse Assay, Activity Assay
Figure Legend Snippet: Inhibition of angiogenesis in vivo ). Macroscopic appearance of representative sample of matrigel alone (negative control) ( A ), matrigel plus bFGF (positive control) ( B ), matrigel plus bFGF plus low-dose CTX ( C ), and matrigel plus bFGF plus MTD CTX ( D ). Quantification of intravascular FITC content showed a significant inhibition of neovascularization in wild-type mice treated with a low-dose CTX regimen ( E ) but a complete lack of antiangiogenic activity of the same regimen (CTX 25) in TSP-1-null mice, whereas MTD CTX (CTX 150) retained activity in these mice ( F ). Shown are mean values ± SD ( * , P
Techniques Used: Inhibition, In Vivo, Negative Control, Positive Control, Mouse Assay, Activity Assay
Figure Legend Snippet: ( A ) Effect of two different metronomic chemotherapy regimens (continuous administration of CTX 20 mg/kg p.o. or VBL 0.3 mg/kg administered three times a week) and their combination at the same doses (CTX + VBL) or consecutively and alternatively (CTX/VBL) in human PC-3 tumor xenografts. At day 20, treatment was started (arrow), and at days 40 and 41, mice were bled from the retroorbital sinus, and tumor volumes were measured, respectively (gray rectangle). ( B ) The TSP-1-competitive enzyme immunoassay was performed on those blood samples, and the results are given as the ratio of TSP-1 plasma concentration to tumor volume. The ratio significantly increased in all treated groups and strongly correlated with the response to the low-dose metronomic chemotherapy regimens. Shown are mean values ± SD ( * , P
Techniques Used: Mouse Assay, Enzyme-linked Immunosorbent Assay, Concentration Assay